99-24980. Request for Nominations for Members on Public Advisory Panels or Committees; Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee  

  • [Federal Register Volume 64, Number 186 (Monday, September 27, 1999)]
    [Notices]
    [Pages 52098-52099]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 99-24980]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    
    Request for Nominations for Members on Public Advisory Panels or 
    Committees; Molecular and Clinical Genetics Panel of the Medical 
    Devices Advisory Committee
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Notice.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is announcing the 
    establishment of the Molecular and Clinical Genetics Panel of the 
    Medical Devices Advisory Committee (the Panel) in the Center for 
    Devices and Radiological Health (CDRH). In this document, FDA is also 
    requesting nominations for members to serve on the newly formed panel.
        FDA has a special interest in ensuring that women, minority groups, 
    and individuals with disabilities are adequately represented on 
    advisory committees and, therefore, encourages nominations of qualified 
    candidates from these groups. Final selection from among qualified 
    candidates for each vacancy will be determined by the expertise 
    required to meet specific agency needs and in a manner to ensure 
    appropriate balance of membership.
    
    DATES: Nominations should be received by October 27, 1999.
    
    ADDRESSES: All nominations and curricula vitae, except for consumer-
    nominated and industry-nominated members, should be sent to Nancy J. 
    Pluhowski (address below). All nominations and curricula vitae for the 
    consumer-nominated members should be sent to Annette J. Funn (address 
    below). All nominations for the industry-nominated members should be 
    sent to Kathleen L. Walker (address below).
    
    FOR FURTHER INFORMATION CONTACT:
        Regarding all nominations for membership, except consumer-nominated 
    and industry-nominated members: Nancy J. Pluhowski, Office of Device 
    Evaluation (HFZ-400), CDRH, Food and Drug Administration, 9200 
    Corporate Blvd., Rockville, MD 20850, 301-594-2022.
        Regarding all nominations for consumer-nominated members: Annette 
    J. Funn, Office of Consumer Affairs (HFE-88), Food and Drug 
    Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-5006.
        Regarding all nominations for industry-nominated members: Kathleen 
    L. Walker, Office of Systems and Management (HFZ-17), CDRH, Food and 
    Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301-594-
    1283, ext. 114.
    
    SUPPLEMENTARY INFORMATION: The Panel was created on August 18, 1999. 
    FDA is requesting nominations for members to serve on the new advisory 
    panel. Persons nominated for membership should have expertise in the 
    activity of the Panel as identified below.
    
    Functions
    
        The functions of the medical devices panels of the Medical Devices 
    Advisory Committee are to: (1) Review and evaluate data on the safety 
    and effectiveness of marketed and investigational devices and make 
    recommendations for their regulation; (2) advise the Commissioner of 
    Food and Drugs regarding recommended classification or reclassification 
    of these devices into one of three regulatory categories; (3) advise on 
    any possible risks to health associated with the use of devices; (4) 
    advise on formulation of product development protocols; (5) review 
    premarket approval applications for medical devices; (6) review 
    guidelines and guidance documents; (7) recommend exemption to certain 
    devices from the application of portions of the Federal Food, Drug, and 
    Cosmetic Act (the act); (8) advise on the necessity to ban a device; 
    (9) respond to requests from the agency to review and make 
    recommendations on specific issues or problems concerning the safety 
    and effectiveness of devices; and (10) make recommendations on the 
    quality in the design of clinical studies regarding the safety and 
    effectiveness of marketed and investigational devices.
        Specifically, the function of the Molecular and Clinical Genetics 
    Panel is to provide advice to the Commissioner on the appropriate 
    scientific criteria to diagnostically test for human genes. In addition 
    to the functions of the Medical Devices Advisory Committee, this panel 
    shall review guidance and recommend criteria and classification of 
    tests for human genes.
    
    Criteria for Members
    
        Persons nominated for membership on the Panel shall have expertise 
    in human genetics and in the clinical management of patients with 
    genetic disorders, e.g., pediatricians, obstetricians, and 
    neonatologists. The agency is also interested in considering
    
    [[Page 52099]]
    
    candidates with training in inborn errors of metabolism, biochemical 
    and/or molecular genetics, population genetics, epidemiology and 
    related statistical training. Additionally, individuals with experience 
    in genetic counseling, medical ethics as well as ancillary fields of 
    study will be considered. The term of office is up to 4 years.
        The Panel will also include technically qualified members who are 
    identified with consumer interests and representatives of industry 
    interests.
    
    Nomination Procedures
    
        Any interested person may nominate one or more qualified persons 
    for membership on the Panel. Self-nominations are also accepted. 
    Nominations shall include a complete curriculum vitae of each nominee, 
    current business address and telephone number, and shall state that the 
    nominee is aware of the nomination, is willing to serve as a member, 
    and appears to have no conflict of interest that would preclude Panel 
    membership. FDA will ask the potential candidates to provide detailed 
    information concerning such matters as financial holdings, employment, 
    and research grants and/or contracts to permit evaluation of possible 
    sources of conflict of interest.
    
    Criteria for Consumer-Nominated Members
    
        Selection of members representing consumer interests is conducted 
    through procedures that include use of a consortium of consumer 
    organizations which has the responsibility for screening, interviewing 
    and recommending candidates for the agency's selection. Candidates from 
    this group, like all other candidates for membership on the Panel, 
    should possess appropriate qualifications to understand and contribute 
    to the Panel's work.
    
    Industry Representatives
    
        Regarding nominations for members representing industry interests, 
    a letter will be sent to each person or organization that has made a 
    nomination and to other organizations that have expressed an interest 
    in participating in the selection process together with a complete list 
    of all such organizations and the nominees. The letter will state that 
    it is the responsibility of each nominator or organization that has 
    expressed an interest in participating in the selection process to 
    consult with the others to provide a consensus slate of possible 
    members representing industry interests within 60 days. In the event 
    that a slate of nominees has not been provided within 60 days, the 
    agency will select an industry representative for each such vacancy 
    from the entire list of industry nominees to avoid delay or disruption 
    of the work of the Panel. The agency is particularly interested in 
    nominees that possess the essential scientific credentials needed to 
    participate fully and knowledgeably in the Panel's deliberations. In 
    addition to this expertise, the agency believes that it would be an 
    advantage to the Panel's work if the individual had special insight and 
    direct experience into specific industrywide issues, practices, and 
    concerns that might not otherwise be available to others not similarly 
    situated.
        This notice is issued under the Federal Advisory Committee Act (5 
    U.S.C. app. 2) and 21 CFR part 14 relating to advisory committees.
    
        Dated: September 17, 1999.
    Linda A. Suydam,
    Senior Associate Commissioner.
    [FR Doc. 99-24980 Filed 9-24-99; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Published:
09/27/1999
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
99-24980
Dates:
Nominations should be received by October 27, 1999.
Pages:
52098-52099 (2 pages)
PDF File:
99-24980.pdf